References
Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72, 1283–1293.
Brenneman D. E., Spong C. Y., Hauser J. M., Abebe D., Pinhasov A., Golian T., and Gozes I. (2004) Protective peptides that are orally active and mechanistically non-chiral. J. Pharmacol. Exp. Ther. March 8, 2004 [Epub ahead of print].
Chen Y., Lomnitski L., Michaelson D. M., and Shohami E. (1997) Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 80, 1255–1262.
Fisher A., Brandeis R., Chapman S., Pittel Z., and Michaelson D. M. (1998) M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J. Neurochem. 70, 1991–1997.
Genis I., Fisher A., and Michaelson D. M. (1999) Sitespecific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J. Neurochem. 72, 206–213.
Gordon I., Grauer E., Genis I., Sehayek E., and Michaelson D. M. (1995) Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci. Lett. 199, 1–4.
Gozes I., Bachar M., Bardea A., Davidson A., Rubinraut S., Fridkin M., and Giladi E. (1997) Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implication for early treatment of Alzheimers disease. J. Neurobiol. 33, 329–342.
Gozes I. and Brenneman D. E. (2000) A new concept in neuroprotection. J. Molec. Neurosci. 14, 61–68.
Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D. E., and Spier A.D. (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Molec. Neurosci. 20, 315–322.
Gozes I., Perl O., Giladi E., Davidson A., Ashur-Fabian O., Rubinraut S., and Fridkin M. (1999) Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl. Acad. Sci. USA 96, 4143–4148.
Grootendorst J., de Kloet E. R., Dalm S., and Oitzl M. S. (2001) Reversal of cognitive deficit of apolipoprotein E knockout mice after repeated exposure to a common environmental experience. Neuroscience 108, 237–247.
Author information
Authors and Affiliations
Additional information
Preclinical studies related to NAP were supported in part by the Institute for the Study of Aging (ISOA), Allon Therapeutics, Inc., NIA, and NICHD. Professor Illana Gozes serves as the Chief Scientific Officer of Allon Therapeutics, Inc. This short editorial is by no means a comprehensive literature review. Rather, it highlights aspects of the ApoE knockout mice as an animal model capturing facets of Alzheimer’s disease that can be used for the assessments of candidate protective molecules.
Rights and permissions
About this article
Cite this article
Gozes, I. Apolipoprotein E knockout mice as a model of behavioral dysfunction. J Mol Neurosci 23, 149–150 (2004). https://doi.org/10.1385/JMN:23:3:149
Issue Date:
DOI: https://doi.org/10.1385/JMN:23:3:149